CN119909065A - 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 - Google Patents
治疗和减轻酒精诱导的皮肤潮红的组合物和方法 Download PDFInfo
- Publication number
- CN119909065A CN119909065A CN202411836532.9A CN202411836532A CN119909065A CN 119909065 A CN119909065 A CN 119909065A CN 202411836532 A CN202411836532 A CN 202411836532A CN 119909065 A CN119909065 A CN 119909065A
- Authority
- CN
- China
- Prior art keywords
- subject
- pharmaceutical composition
- alcohol
- aldh2
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852000P | 2019-05-23 | 2019-05-23 | |
| US62/852,000 | 2019-05-23 | ||
| CN202080052527.2A CN114144493A (zh) | 2019-05-23 | 2020-05-22 | 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 |
| PCT/US2020/034273 WO2020237172A1 (en) | 2019-05-23 | 2020-05-22 | Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080052527.2A Division CN114144493A (zh) | 2019-05-23 | 2020-05-22 | 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119909065A true CN119909065A (zh) | 2025-05-02 |
Family
ID=73458156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411836532.9A Pending CN119909065A (zh) | 2019-05-23 | 2020-05-22 | 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 |
| CN202080052527.2A Pending CN114144493A (zh) | 2019-05-23 | 2020-05-22 | 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080052527.2A Pending CN114144493A (zh) | 2019-05-23 | 2020-05-22 | 治疗和减轻酒精诱导的皮肤潮红的组合物和方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220226286A1 (https=) |
| EP (1) | EP3973030A4 (https=) |
| JP (2) | JP2022536408A (https=) |
| KR (1) | KR20220012903A (https=) |
| CN (2) | CN119909065A (https=) |
| TW (1) | TW202110437A (https=) |
| WO (1) | WO2020237172A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102879756B1 (ko) | 2022-11-11 | 2025-11-12 | 대한민국 | 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도 |
| KR102893400B1 (ko) | 2022-11-21 | 2025-12-02 | 대한민국 | 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6468319A (en) * | 1987-09-09 | 1989-03-14 | Nonogawa Shoji Yk | Anti-inflammatory |
| JPH01287035A (ja) * | 1988-05-13 | 1989-11-17 | Sanwa Kagaku Kenkyusho Co Ltd | 薬物並びにアルコール性中毒の予防剤とその治療剤 |
| TW271400B (https=) * | 1992-07-30 | 1996-03-01 | Pfizer | |
| IT1306133B1 (it) * | 1999-04-22 | 2001-05-30 | Sigma Tau Healthscience Spa | Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento. |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| US20110053999A1 (en) * | 2004-03-03 | 2011-03-03 | Daley Thomas E | 4-methylpyrazole formulations for inhibiting ethanol intolerance |
| CN101232822B (zh) * | 2005-07-29 | 2012-11-14 | 蒂马基金会 | 用于减缓乙醇代谢和用于降低乙醇诱导的疾病风险的组合物 |
| KR20090117950A (ko) * | 2007-03-08 | 2009-11-16 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법 |
| JP2011051942A (ja) * | 2009-09-03 | 2011-03-17 | Glovia:Kk | 認知症治療薬 |
| JPWO2011043365A1 (ja) * | 2009-10-07 | 2013-03-04 | 学校法人武庫川学院 | 遺伝子型判定方法 |
| EP2467136B1 (en) * | 2009-12-07 | 2014-05-07 | Raptor Therapeutics Inc. | 4-methylpyrazole formulations |
| MX2013002162A (es) * | 2010-08-24 | 2013-04-05 | Univ California | Metodos para tratar la intoxicacion con alcohol, transtornos debido al consumo de alcohol y alcolismo que comprenden la administracion de dihidromiricetina. |
| FI128082B (en) * | 2014-09-15 | 2019-09-13 | Biohit Oyj | Preparations for the treatment and prevention of alcohol redness and alcohol-induced hypersensitivity reactions |
| EP3323412A1 (en) * | 2016-11-17 | 2018-05-23 | Amalicon Holding AG | Formulation comprising 4-methylpyrazole |
-
2020
- 2020-05-22 TW TW109117085A patent/TW202110437A/zh unknown
- 2020-05-22 JP JP2022515975A patent/JP2022536408A/ja active Pending
- 2020-05-22 KR KR1020217042000A patent/KR20220012903A/ko not_active Withdrawn
- 2020-05-22 CN CN202411836532.9A patent/CN119909065A/zh active Pending
- 2020-05-22 CN CN202080052527.2A patent/CN114144493A/zh active Pending
- 2020-05-22 WO PCT/US2020/034273 patent/WO2020237172A1/en not_active Ceased
- 2020-05-22 EP EP20810476.0A patent/EP3973030A4/en not_active Withdrawn
- 2020-05-22 US US17/613,680 patent/US20220226286A1/en active Pending
-
2025
- 2025-03-05 JP JP2025034659A patent/JP2025093991A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020237172A1 (en) | 2020-11-26 |
| JP2025093991A (ja) | 2025-06-24 |
| CN114144493A (zh) | 2022-03-04 |
| US20220226286A1 (en) | 2022-07-21 |
| KR20220012903A (ko) | 2022-02-04 |
| TW202110437A (zh) | 2021-03-16 |
| JP2022536408A (ja) | 2022-08-15 |
| EP3973030A1 (en) | 2022-03-30 |
| EP3973030A4 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190231766A1 (en) | Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate | |
| US9925174B2 (en) | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof | |
| AU2004258984B2 (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
| ES2347968T3 (es) | Preparacion solida que se disgrega rapidamente. | |
| JP4454791B2 (ja) | 医薬製剤 | |
| JP2025093991A (ja) | アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 | |
| CN102802418A (zh) | 用于治疗肌萎缩性侧索硬化的组合物和方法 | |
| RU2690685C2 (ru) | Фармацевтические композиции, содержащие алпелисиб | |
| BR112019023101A2 (pt) | composições farmacêuticas e métodos de tratamento para doenças cardiovasculares | |
| NO342977B1 (no) | Racecadotriltablett, fremgangsmåte for fremstilling av slike og slike tabletter for behandling av diaré | |
| EP3429559A1 (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
| AU2024227367A1 (en) | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| KR20140068037A (ko) | 누난 증후군의 치료를 위한 유기 화합물의 용도 | |
| JP5101306B2 (ja) | 糖尿病治療剤 | |
| CN100431526C (zh) | 一种酸敏感型药物的快速崩解片剂 | |
| TW200920348A (en) | Combination of picotamide with nafronyl | |
| KR20240070564A (ko) | 알츠하이머병 예방 또는 치료용 약학적 조성물 | |
| WO2012154174A1 (en) | Methods for treating insomnia | |
| JP2009007311A (ja) | ジフェンヒドラミン−アセスルファム付加物、その製造方法及び該付加物を含有する経口製剤 | |
| HK40111138A (zh) | 含有非索非那定的组合物 | |
| MXPA06005084A (en) | Combination of proton pump inhibitor and sleep aid | |
| JP2012219075A (ja) | ナフトピジルを含有する医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |